Table 2

Monthly quantity and market share of cholesterol-lowering drug classes in 2012 and 2015

Mean monthly quantity and market share20122015P value
HMG-CoA reductase inhibitors, tablets/month (%)269 948.8±19 340.3 (71.14)343 975.3±34 612.5 (72.91)<0.001
Fibrates, tablets/month (%)73 243.2±4972.8 (19.30)79 711.3±6391.4 (16.89)0.011
Cholesterol absorption inhibitors, tablets/month (%)36 243.0±3644.9 (9.55)43 098.8±5095.6 (9.13)0.001
Niacin, tablets/month (%)5024.0±5162.0 (1.06)0.006
Atorvastatin, tablets/month (%)68 032.3±4772.6 (22.18)84 406.8±7321.5 (22.17)<0.001
Rosuvastatin, tablets/month (%)94 952.6±6657.1 (30.96)121 829.9±9972.9 (32.00)<0.001
Simvastatin, tablets/month (%)15 990.6±1301.6 (5.21)12 100.8±1120.0 (3.18)<0.001
Pitavastatin, tablets/month (%)34 113.4±7507.4 (8.96)<0.001
Fluvastatin, tablets/month (%)45 929.8±3298.2 (14.98)38 754.3±2844.0 (10.18)<0.001
Ezetimibe, tablets/month (%)8516.4±636.8 (2.78)9757.5±1095.6 (2.56)0.003
Fenofibrate, tablets/month (%)38 069.8±2429.4 (12.41)40 854.9±3085.2 (10.73)0.022
Gemfibrozil, tablets/month (%)35 173.3±3056.0 (11.47)38 856.3±3437.9 (10.21)0.011
  • Mean±SD represents the number of patients receiving a particular cholesterol-lowering drug in 1 month.

  • HMG-CoA, 3-hydroxy-3-methylglutaryl- coenzyme-A.